XML 55 R38.htm IDEA: XBRL DOCUMENT v3.25.4
Summary of Significant Accounting Policies - Narrative (Details) - USD ($)
 1 Months Ended 3 Months Ended 12 Months Ended
May 31, 2025
Oct. 31, 2024
Sep. 30, 2022
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Property, Plant and Equipment [Line Items]            
Allowance for credit loss       $ 0    
Amortization of intangible assets       4,667,000 $ 1,959,000 $ 750,000
Impairment losses       0 0 0
Tangible asset impairment charges       0 0 0
Advertising costs       25,300,000 6,900,000 11,200,000
Unrecognized tax benefits, income tax penalties and interest expense       0 0 0
AstraZeneca            
Property, Plant and Equipment [Line Items]            
Product milestone payment for first product approval     $ 7,500,000      
Intangible asset, useful life (in years)     10 years      
Sales milestone payment $ 10,000,000.0 $ 5,000,000.0        
Annual net sales $ 250,000,000.0 $ 100,000,000.0        
Amortization of intangible assets       $ 4,700,000 $ 2,000,000.0 $ 800,000
Patents | AstraZeneca            
Property, Plant and Equipment [Line Items]            
Intangible asset, useful life (in years)       10 years    
Minimum            
Property, Plant and Equipment [Line Items]            
Useful life (in years)       2 years    
Payment terms (in days)       30 days    
Maximum            
Property, Plant and Equipment [Line Items]            
Useful life (in years)       5 years    
Payment terms (in days)       65 days